Name change announcement, news from the CEO

It has now been just over a year since InterVivo Solutions (headquartered in Toronto, Canada) acquired Transpharmation, (headquartered in London, UK) bringing together two Neuroscience-centric Contract Research Organisations (CROs). This has enabled us to deliver a wider set of capabilities, along with an even deeper knowledge base, to assist our clients in the Global Pharmaceutical, Animal Health and Biotech Sectors.

From today, we are delighted to announce the following changes. InterVivo Solutions will change its name to Transpharmation Canada and will sit alongside the three European Transpharmation businesses: Transpharmation UK, Transpharmation Ireland and Transpharmation Poland.

On our new website you’ll find details of the wide range of preclinical services on offer, all our publications and posters, scientific and newsworthy study based newsletters and much more. You will also see our emails change to addresses and our logo now acknowledges our parent company. Mark Duxon CEO revealed, “We are hugely excited about the opportunities that this transformation offers our clients and we would be delighted to discuss these with you at the Society for Neuroscience event later this month in San Diego, should you be attending.”

If you have any questions, please reach out to a member of our team and we will be happy to discuss any aspect of the changes.